NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity RFA-DK-23-013 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIDDK R25 program is to support educational activities that help recruit individuals with specific specialty or disciplinary backgrounds to research careers in biomedical, behavioral and clinical sciences.To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Research Experiences. This FOA solicits applications to establish summer research institutes for qualified undergraduates to participate in summer research experiences relevant to the mission of the Division of Kidney, Urologic and Hematologic Diseases/NIDDK (NIDDK/DKUH).
Funding Opportunity RFA-CA-23-024 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO), issued by the National Cancer Institute (NCI), is to invite competing continuation applications for cooperative agreement awards from current recipients of the NCI-supported Cooperative Human Tissue Network (CHTN). CHTN with all individual CHTN recipients (referred to as CHTN Divisions) collectively form the CHTN national resource. Presently, the organizational structure of the Network comprises six Divisions. The goal of the CHTN is to collect and distribute to investigators high-quality human tissue specimens to facilitate basic and translational cancer research. Such specimens may be needed for scientific discovery and the development of various molecular diagnostic tests, and prognostic or predictive assays. The CHTN is designed as a unique biospecimen resource in that it is based on the prospective collection and distribution of samples upon specific investigators requests. Samples to be collected from patients include pre-cancerous, malignant, and benign neoplastic tissues, as well as tissues with non-neoplastic diseases and normal tissues. Since its establishment by the NCI in 1987, the CHTN has provided more than 1,350,000 malignant, benign, diseased, and uninvolved (normal adjacent) high-quality human tissue specimens from a wide variety of organ sites to over four thousand investigators.
Notice NOT-OD-23-137 from the NIH Guide for Grants and Contracts
Notice NOT-MD-23-015 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AG-24-032 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to further our understanding of how different behavioral, social, cultural, environmental, and institutional factors affect the trajectory of cognitive aging and Alzheimers disease (AD) and AD-related dementias (AD/ADRD) and the experience of living with or managing AD/ADRD in different national or regional contexts. Specifically, NIA seeks to support analyses of data from the Harmonized Cognitive Assessment Protocol (HCAP) from the US or another country where HCAP data is available or to perform cross-national analyses.
Notice NOT-HG-23-045 from the NIH Guide for Grants and Contracts
Notice NOT-HG-23-044 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DK-23-020 from the NIH Guide for Grants and Contracts. This NOFO invites applications for a Biostatistics Research Center to participate in ?a? ?consortium aimed at improving understanding of heterogeneity of type 2 diabetes (T2D). A separate NOFO (RFA-DK-23-019) will bring together investigative teams for integration of multiple data types, including markers of organ or tissue function, into analysis approaches for stratifying individuals T2D and developing more precise definitions of disease. The ultimate goal of this effort will be to 1) develop a broadly applicable framework for identifying subtypes of T2D; and 2) increase understanding ofthe physiologic drivers of T2D subtypes to guide development of more effective precision interventions.
Funding Opportunity RFA-DK-23-019 from the NIH Guide for Grants and Contracts. The purpose of this NOFO is to create a consortium to bring together investigative teams for integration of multiple data types, including markers of organ or tissue function, into analysis approaches for stratifying individuals with type 2 diabetes (T2D) and developing more precise definitions of disease. The ultimate goal of this effort will be to 1) develop a broadly applicable framework for identifying subtypes of T2D; and 2) increase understanding ofthe physiologic drivers of T2D subtypes to guide development of more effective precision interventions.
Notice NOT-DK-23-022 from the NIH Guide for Grants and Contracts
Notice NOT-HS-23-015 from the NIH Guide for Grants and Contracts
Notice NOT-HG-23-043 from the NIH Guide for Grants and Contracts
Notice NOT-RM-23-013 from the NIH Guide for Grants and Contracts
Notice NOT-DK-23-027 from the NIH Guide for Grants and Contracts
Notice NOT-DK-23-026 from the NIH Guide for Grants and Contracts
Notice NOT-DE-23-012 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-23-184 from the NIH Guide for Grants and Contracts. The Center for Inherited Disease Research (CIDR) high-throughput genotyping, sequencing and supporting statistical genetics services are designed to aid the identification of genes or genetic modifications that contribute to human health and disease or to enhance existing collections of well-phenotyped specimens in biorepositories by the addition of genotype or next-generation sequence data. The laboratory specializes in genomic services that cannot be efficiently carried out in individual investigator laboratories. CIDR provides the most up-to-date platforms, services and statistical genetic support. This is an NIH-wide initiative that is managed by NHGRI. Information about current services offered can be accessed via: http://www.cidr.jhmi.edu.
Funding Opportunity PAR-23-126 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages grant applications that support the activities of the National Primate Research Centers (NPRCs). Nonhuman primates (NHPs) are most closely related to humans, both physiologically and genetically. Therefore, NHPs are critical animal models for basic and translational research aimed at understanding human biology, both in normal and diseased states. Proper husbandry and management of NHPs require specialized physical and intellectual resources, which are most effectively and economically provided in centralized primate centers, the resources of which are made available to investigators on a national basis. The NPRCs provide these resources to investigators/grantees who utilize NHPs in biomedical research and thereby complement and help enable the missions of the NIH Institutes and Centers.
Funding Opportunity PAR-23-204 from the NIH Guide for Grants and Contracts. The NEI uses UG1 cooperative agreement awards to support investigator-initiated large-scale clinical trials, human gene-transfer, stem cell therapy trials, and other complex or high resource- or safety-risk clinical trials. These projects are multifaceted and of high public health significance requiring clear delineation of study organization including roles and responsibilities and require careful performance oversight and monitoring. For purposes of this Notice of Funding Opportunity (NOFO), the proposed study must be intended to evaluate interventions aimed at screening, diagnosing, preventing, or treating vision disorders, or to compare the effectiveness of two or more established interventions. The NEI UG1-supported studies are typically funded as a group of single-component companion grant awards including the Chairs Grant, the Coordinating Center, and Resource Centers, when appropriate. Specifically, this NOFO encourages applications for the Coordinating Center grant, which provides details of the Coordinating Center's responsibilities and operations.
Funding Opportunity PAR-23-201 from the NIH Guide for Grants and Contracts. The NEI uses UG1 cooperative agreement awards to support investigator-initiated large-scale clinical trials, human gene-transfer, stem cell therapy trials, and other complex or high resource- or safety-risk clinical trials. These projects are multifaceted and of high public health significance requiring clear delineation of study organization including roles and responsibilities and require careful performance oversight and monitoring. For purposes of this Notice of Funding Opportunity (NOFO), the proposed study must be intended to evaluate interventions aimed at screening, diagnosing, preventing, or treating vision disorders, or to compare the effectiveness of two or more established interventions. The NEI UG1-supported studies are typically funded as a group of single-component companion grant awards including the Chairs Grant, the Coordinating Center, and Resource Centers, when appropriate. Specifically, this NOFO encourages applications for the Resource Center grant which provides imaging, laboratory, or other requisite services for a multi-center clinical trial or other complex or high-risk clinical trial.